Evidence-based treatments for gastrointestinal diseases

We are building a pipeline of evidence-based gastrointestinal health products, through in-house development and in-licencing / partnership opportunities.


Stage 2 IBS Clinical Trial Phase II

Irritable Bowel Syndrome (IBS) trial

We are thrilled to announce that Anatara Lifesciences is now accepting applications for Stage 2 of our clinical trial on Irritable Bowel Syndrome (IBS).

By joining Stage 2 of our clinical trial, you can play a pivotal role in advancing IBS treatment options and potentially improve the quality of life for millions of individuals worldwide.


Positive Outcome for Stage 1 GaRP Trial

Irritable Bowel Syndrome trial
has reached interim

We’re delighted to share that Stage 1 of the GaRP Irritable Bowel Syndrome (IBS) trial has reached its conclusion. 

Anatara’s GaRP-IBS trial moves to Stage 2 with strong preliminary efficacy results. Patients on the low dose saw a 56% reduction in IBS-SSS scores, outperforming the placebo group by 20%. Promising news for IBS sufferers!

Our commitment to improving lives through research is stronger than ever.

As seen on

about IBS

Irritable Bowel Syndrome

Irritable Bowel Syndrome (IBS) is the most commonly diagnosed gastrointestinal condition and a significant cost burden on health care.



Irritable Bowel Syndrome affects around 1 in 9 people


Meet Anatara

Innovative Solutions for Gastrointestinal Health:
Anatara Lifesciences (ASX: ANR)

Anatara Lifesciences (ASX: ANR) specialises in creating evidence-based, innovative products to address unmet needs in gastrointestinal health for both humans and animals. Our focus is on building a pipeline of gastrointestinal health products through our own research and development as well as strategic partnerships. Our core commitment is to deliver tangible benefits to patients and create significant value for our shareholders.

& Pipelines

Developing products
for gastrointestinal health

Anatara Lifesciences is developing evidence based solutions for gastrointestinal diseases in humans and animals. Click below to discover more about our innovative approaches, cutting-edge technologies, and our mission to make a meaningful impact on gastrointestinal health.

Irritable Bowel


Latest news

Your news and information

Explore our news and information section to stay connected with our latests updates.

investor home

ASX Announcements


Annual General Meeting 2023

investor home

Annual Reports

Evidence-based treatments for
gastrointestinal diseases
Want to stay up to date with our trials and latest news?
Sign up here

    All rights reserved © Anatara Lifesciences 2023